Article info
PDFReview
Lack of evidence for a link between latanoprost use and malignant melanoma: an analysis of safety databases and a review of the literature
- Correspondence to Charles S Tressler, Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA; charles.s.tressler{at}pfizer.com
Citation
Lack of evidence for a link between latanoprost use and malignant melanoma: an analysis of safety databases and a review of the literature
Publication history
- Accepted March 20, 2011
- First published April 21, 2011.
Online issue publication
October 21, 2011
Article Versions
- Previous version (21 April 2011).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.